Kairos Pharma, LTD. (KAPA)

SEC fundamentals · as filed in 10-Q FY2026, period ended Jun 30, 2026 · updated Oct 7, 2026

Verified against EDGAR
Total Assets
$4.5M
Stockholders' Equity
$4.2M
Cash & Equivalents
$2.6M
Long-Term Debt
—

as filed in 10-Q FY2026, period ended Jun 30, 2026 · View filings on EDGAR ↗

In its 10-Q for the period ended Jun 30, 2026, Kairos Pharma, LTD. reported net income of -$1.4M and total assets of $4.5M. Every figure below is taken directly from Kairos Pharma, LTD.'s SEC filings: each links to the source document on EDGAR.

Revenue and net income by fiscal year

As reported in each year’s annual filing · USD

Fiscal yearRevenueNet income
FY2025—-$5.4M
FY2024—-$2.6M
FY2023—-$1.8M

Recent SEC filings

Filed by the registrant · newest first · insider forms and holder schedules not included

FormFiledSource
8-KOct 6, 2026on EDGAR ↗
8-KSep 14, 2026on EDGAR ↗
8-KAug 21, 2026on EDGAR ↗
10-QAug 12, 2026on EDGAR ↗
8-KJul 22, 2026on EDGAR ↗
8-KJul 15, 2026on EDGAR ↗
8-KJun 30, 2026on EDGAR ↗
8-KJun 4, 2026on EDGAR ↗
DEF 14AMay 22, 2026on EDGAR ↗
8-KMay 18, 2026on EDGAR ↗

All filings on EDGAR ↗

Balance Sheet

as of Jun 30, 2026 · 10-Q

Total Assets$4.5Msource ↗
Stockholders’ Equity$4.2Msource ↗
Cash & Equivalents$2.6Msource ↗
Long-Term Debt—source ↗

Income Statement

10-Q (quarterly) · period ended Jun 30, 2026

Revenue—source ↗
Net Income-$1.4Msource ↗
Operating Income-$1.4Msource ↗
Gross Profit—source ↗
Cost of Revenue—source ↗
R&D Expense$619,000source ↗

Per Share & Cash Flow

10-Q (quarterly) · period ended Jun 30, 2026

EPS (diluted)$-0.06source ↗
EPS (basic)$-0.06source ↗
Shares Outstanding23.7Msource ↗
Cash from Operations-$1.0Msource ↗
Cash from Financing-$37,000source ↗
Cash from Investing—source ↗

Restatement history

Point-in-time

1 of 60 annual fact-keys were materially restated between filings: what Kairos Pharma, LTD. first reported differed from what it later filed. We keep every vintage of every annual figure, each keyed to its EDGAR accession.

See each original-vs-restated value, and query any company as of any past date, with the point-in-time API.

See the restatement detail →

Deeper fundamentals

A free API key reaches KAPA’s revenue, margin and free-cash-flow trajectory (newest 3 fiscal years) and its leverage, liquidity and return ratios (newest 4 quarters). Analyst extends those to up to 20 years and 20 quarters, and adds the Piotroski F-score and accruals quality score. As-of fundamentals at any past date are on Free too, up to 10 lookups a day; Analyst removes that cap and adds the original-vs-restated detail, across the whole SEC universe.

Get a free API key →See plans

Programmatic access

Everything on this page is served by the Distill API and by the MCP server at mcp.distillmarkets.com. A free key is issued at sign-up with no card; the full reference is in the docs.

These fundamentals, as filed
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/fundamentals/KAPA

MCP tool: get_sec_fundamentals ticker=KAPA

The same figures as they were known on any past date
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/fundamentals/KAPA/as-of/YYYY-MM-DD

MCP tool: get_asof_fundamentals ticker=KAPA as_of=YYYY-MM-DD

Fiscal-year trajectory: revenue, margins, free cash flow
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/fundamentals/KAPA/history

MCP tool: get_fundamentals_history ticker=KAPA

Leverage, liquidity, margin and return ratios
curl
curl -H "X-Api-Key: $DISTILL_API_KEY" \
  https://api.distillmarkets.com/api/v1/sec/financial-health/KAPA

MCP tool: get_financial_health ticker=KAPA

Not investment advice. Figures are shown as filed with the SEC; see the EDGAR source links for the original documents. Data may lag the latest filing.